teserpaturev

AXP000002.1 · Oncolytic virus

Platform
HSV-1 (G47delta, triple-mutated: gamma34.5, ICP6, alpha47)
Originator
The University of Tokyo (Tomoki Todo)
Sponsor
Daiichi Sankyo

Names

NameTypeSource
teserpaturevpreferred name, INNcurator, ncit
Delytactbrandpress
DS-1647codepress
G47∆codepress

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
F
Replication
conditionally replicating
Modifications
both copies of RL1 (gamma34.5) deleted; UL39 (ICP6) inactivated by lacZ insertion; US12 (ICP47) deleted
Transgenes
LacZ
Route
intratumoral, intracerebral
Source
evidence

Cross-references

NCI Thesaurus
C190358
Wikidata
Q116044341
FDA UNII
6S57D3Y2F5

Approvals

AgencyRegionDateStatusBrandIndicationSource
PMDAJP2021-06-11conditionalDelytactMalignant glioma (conditional, time-limited approval)source

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42885740Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR.Oncotarget2026name in abstract: teserpaturev
PMID 36917020Regulatory Issues: PMDA - Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma.The oncologist2023name in title: teserpaturev
PMID 35864115A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma.Nature communications2022name in title: G47∆
PMID 35864254Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.Nature medicine2022name in title: G47∆

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41675687Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery.Molecular therapy. Oncology2026name in abstract: teserpaturev
PMID 41901211Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines.Pharmaceuticals (Basel, Switzerland)2026name in abstract: teserpaturev
PMID 42025901Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects.Clinica chimica acta; international journal of clinical chemistry2026name in abstract: Delytact
PMID 42216079Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies.Virology journal2026name in abstract: teserpaturev
PMID 42440296Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma: A Review.JAMA neurology2026name in abstract: teserpaturev
PMID 43005928The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery.RSC advances2026name in abstract: teserpaturev
PMID 40102594Author Correction: Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.Nature medicine2025name in title: G47∆
PMID 40285023Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus.Viruses2025name in abstract: Delytact
PMID 40702727Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: Delytact
PMID 40872965Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.Vaccines2025name in abstract: teserpaturev
PMID 40881284Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential.Frontiers in microbiology2025name in abstract: teserpaturev
PMID 38896326An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.Current treatment options in oncology2024name in abstract: teserpaturev
PMID 39293238Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers.Virology2024name in abstract: teserpaturev
PMID 36299168Oncolytic virus preclinical toxicology studies.Journal of applied toxicology : JAT2023name in abstract: teserpaturev
PMID 36619294Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors.Molecular therapy oncolytics2023name in title: G47∆
PMID 37194509[Drugs under Development (Neurosurgery)].Brain and nerve = Shinkei kenkyu no shinpo2023name in abstract: Delytact
PMID 37583387Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models.Molecular therapy oncolytics2023name in title: G47∆
PMID 35384530Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.Brain tumor pathology2022name in abstract: Delytact
PMID 35951174The evaluation expression of non-coding RNAs in response to HSV-G47∆ oncolytic virus infection in glioblastoma multiforme cancer stem cells.Journal of neurovirology2022name in title: G47∆
PMID 36098872Teserpaturev/G47Δ: First Approval.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022name in title: teserpaturev
PMID 34675919Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Frontiers in immunology2021name in abstract: teserpaturev
PMID 34853811Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma.Molecular therapy oncolytics2021name in title: G47∆
PMID 23292314The oncolytic herpes simplex virus vector G47∆ effectively targets breast cancer stem cells.Oncology reports2013name in title: G47∆
Unconfirmed matches (18)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41403403Engineering HSV-1 for oncolytic therapy: From molecular entry mechanisms to retargeting strategies.Genes & diseases2026name in abstract: G47∆
PMID 41827827Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation.Cells2026name in abstract: G47∆
PMID 42648642Engineering HSV-1 for gene therapy, oncolytic immunotherapy, and neuroscience.Virologica Sinica2026name in abstract: G47∆
PMID 42886257Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives.Clinical and experimental medicine2026name in abstract: G47∆
PMID 40069043HSV-1 as a gene delivery platform for cancer gene therapy.Trends in pharmacological sciences2025name in abstract: G47∆
PMID 40957170Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.International immunopharmacology2025name in abstract: G47∆
PMID 41228258The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.Cancers2025name in abstract: G47∆
PMID 41463198Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions.Cancers2025name in abstract: G47∆
PMID 38599661Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.Journal for immunotherapy of cancer2024name in abstract: G47∆
PMID 38806994A viral attack on brain tumors: the potential of oncolytic virus therapy.Journal of neurovirology2024name in abstract: G47∆
PMID 36966232Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12.Communications medicine2023name in abstract: G47∆
PMID 35836877Advances in the clinical development of oncolytic viruses.American journal of translational research2022name in abstract: G47∆
PMID 34036669Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.Cancer science2021name in abstract: G47∆
PMID 30462296Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Japanese journal of clinical oncology2019name in abstract: G47∆
PMID 28326624Current status of clinical trials assessing oncolytic virus therapy for urological cancers.International journal of urology : official journal of the Japanese Urological Association2017name in abstract: G47∆
PMID 27486853Oncolytic virus therapy: A new era of cancer treatment at dawn.Cancer science2016name in abstract: G47∆
PMID 24575383Immunovirotherapy for the treatment of glioblastoma.Oncoimmunology2014name in abstract: G47∆
PMID 23754388Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Proceedings of the National Academy of Sciences of the United States of America2013name in abstract: G47∆

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R21NS130429Targeting CD44 signaling in regulating glioblastoma stemness and immune responseAUGUSTA UNIVERSITYHONG, BANGXING B2023–2024name in abstract: Delytact
R21NS123685IGF1R-targeted oncolytic herpes simplex viral therapy for GlioblastomaUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONYOO, JI YOUNG2022–2023name in abstract: Delytact
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
P01CA163205Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapyBRIGHAM AND WOMEN'S HOSPITALKAUR, BALVEEN2023–2026name in abstract: G47∆

Notes

Conditionally approved in Japan 2021 as Delytact. No human transgene (LacZ marker in ICP6); targets left empty. Wikidata has a duplicate item Q110220405 (carries the UNII) beside Q116044341 (the English Wikipedia item).

How to cite

teserpaturev (AXP000002.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000002.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.